Skip to main navigation

Investor Relations

June 07, 2021

Abivax releases the results of its June 4, 2021 ordinary annual and extraordinary general meeting

May 24, 2021

Abivax reports excellent efficacy and safety of ABX464 in phase 2b clinical trial in ulcerative colitis and plans to proceed to phase 3

May 24, 2021

Abivax suspends trading of its shares until the publication of ABX464 Phase 2b results in ulcerative colitis

April 30, 2021

Abivax publishes Universal Registration Document 2021 “Document d’Enregistrement Universel”

April 19, 2021

Abivax Hosting Key Opinion Leader Webinar on ABX464 for the Treatment of Ulcerative Colitis